About Alkermes
Alkermes is a company based in Dublin (Ireland) founded in 1987. The company has 1,800 employees as of December 31, 2024. Alkermes has completed 2 acquisitions, including Avadel Pharmaceuticals and Rodin Therapeutics. Alkermes offers products and services including Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290. Alkermes operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Dublin, Ireland
- Employees 1800 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alkermes Plc
-
Annual Revenue
$1.56 B (USD)-6.36as on Dec 31, 2024
-
Net Profit
$367.07 M (USD)3.18as on Dec 31, 2024
-
EBITDA
$449.17 M (USD)-8.15as on Dec 31, 2024
-
Latest Funding Round
$2.31 M (USD), Grant
Sep 30, 2010
- Investors
-
Employee Count
1800
as on Dec 31, 2024
-
Investments & Acquisitions
Avadel Pharmaceuticals
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Alkermes
Alkermes is a publicly listed company on the NASDAQ with ticker symbol ALKS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Alkermes
Alkermes offers a comprehensive portfolio of products and services, including Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290.
Treatment for schizophrenia and bipolar disorder in adults.
Therapy for narcolepsy and idiopathic hypersomnia conditions.
Investigational treatment for central nervous system disorders.
Potential therapy for neurological and psychiatric issues.
People of Alkermes
Unlock access to complete
Unlock access to complete
Leadership Team
128 people
Software Development Team
119 people
Sales and Marketing
48 people
Senior Team
41 people
Legal and Compliance
23 people
Product Management Team
22 people
Data Analysis and Operations Team
22 people
Operations Team
20 people
Unlock access to complete
Funding Insights of Alkermes
Investors in Alkermes
Alkermes has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for Alkermes
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alkermes
Alkermes has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Avadel Pharmaceuticals and Rodin Therapeutics.
Investment portfolio details for Alkermes
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Epigenetic modulators are developed for CNS disorder treatments.
|
Locked | Locked | 2013 | Locked | |
|
Proprietary drug delivery technologies and narcolepsy treatments are developed.
|
Locked | Locked | 1990 | Locked |
Complete acquisition details for Alkermes
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alkermes
Detailed financials for Alkermes
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alkermes Comparisons
Peer comparison for Alkermes
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alkermes
Alkermes operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Gene and protein therapies are developed for treating various diseases.
|
Detailed competitors of Alkermes
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alkermes
Complete news archive for Alkermes
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alkermes
Alkermes was founded in 1987 and raised its 1st funding round 10 years after it was founded.
Alkermes is headquartered in Dublin, Ireland.
As of Dec 31, 2024, the latest employee count at Alkermes is 1,800.
Annual revenue of Alkermes is $1.56B as on Dec 31, 2024.
Alkermes was founded in 1987 and is based in Dublin, Ireland. Small molecule therapeutics and drug delivery technologies are developed for central nervous system (CNS) diseases. A diversified commercial product portfolio is maintained, alongside a clinical pipeline of candidates for chronic conditions including schizophrenia, depression, addiction, and multiple sclerosis. Operations focus on advancing treatments in the biopharmaceutical sector.
Alkermes's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Alkermes offers Olanzapine and samidorphan, ALKS 2680, ALKS 4510, and ALKS 7290.
Yes, Alkermes is publicly traded on NASDAQ under the ticker symbol ALKS.
Alkermes has made 2 acquisitions, including Avadel Pharmaceuticals, and Rodin Therapeutics.
Alkermes has 1 investor. Key investors include HHS.
The ticker symbol of Alkermes is ALKS on NASDAQ.